{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T07:06:40Z","timestamp":1770534400126,"version":"3.49.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Drugs Ther"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1007\/s10557-016-6681-2","type":"journal-article","created":{"date-parts":[[2016,9,16]],"date-time":"2016-09-16T05:01:43Z","timestamp":1474002103000},"page":"419-426","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Management of Stable Angina \u2013 Current Guidelines: A Critical Appraisal"],"prefix":"10.1007","volume":"30","author":[{"given":"Udho","family":"Thadani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,9,16]]},"reference":[{"key":"6681_CR1","unstructured":"Heberden W. Some account of a disorder of the breast. Medical transitions. Royal College of Physicians; 1772."},{"key":"6681_CR2","doi-asserted-by":"crossref","unstructured":"Thadani U. Current medical management of chronic stable angina pectoris. J Cardiovasc Pharmacol Ther 2004;9 (supplement 1) S11\u2013s29.","DOI":"10.1177\/107424840400900103"},{"issue":"Suppl 1","key":"6681_CR3","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1177\/107424840400900102","volume":"9","author":"LH Opie","year":"2004","unstructured":"Opie LH. Angina pectoris: the evolution of concepts. J Cardiovasc Pharmacol Ther. 2004;9(Suppl 1):S3\u20139.","journal-title":"J Cardiovasc Pharmacol Ther"},{"key":"6681_CR4","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1161\/CIRCULATIONAHA.104.526699","volume":"112","author":"J Abrams","year":"2005","unstructured":"Abrams J, Thadani U. Therapy of stable angina pectoris: the uncomplicated patient. Circulation. 2005;112:e255\u20139.","journal-title":"Circulation"},{"key":"6681_CR5","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1161\/CIRCULATIONAHA.107.187930","volume":"116","author":"TD Fraker","year":"2007","unstructured":"Fraker TD, Fihn ST, et al. 2007 chronic angina focused update of the ACC\/AHA 2002 guidelines for the management of patients with chronic stable angina. Circulation. 2007;116:2762\u201372.","journal-title":"Circulation"},{"key":"6681_CR6","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1161\/CIR.0b013e318277d6a0","volume":"126","author":"SD Fihn","year":"2012","unstructured":"Fihn SD, Garlin JM, Abrams J, et al. ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS guidelines for the diagnosis and management of patients with stable ischemic heart disease. Circulation. 2012;126:e354\u2013471.","journal-title":"Circulation"},{"key":"6681_CR7","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1161\/CIR.0000000000000095","volume":"130","author":"SD Fihn","year":"2014","unstructured":"Fihn SD, Blankenship JC, Alexander KP, et al. 2014 ACCF\/AHA\/ACP\/AATS\/PCNA\/SCAI\/STS focused update of the guidelines for the diagnosis and management of patients with stable ischemic heart disease. Circulation. 2014;130:1749\u201367.","journal-title":"Circulation"},{"key":"6681_CR8","doi-asserted-by":"crossref","first-page":"2949","DOI":"10.1093\/eurheartj\/eht296","volume":"34","author":"G Montalesscot","year":"2013","unstructured":"Montalesscot G, Sechtem U, Achenbachm S, et al. 2013 ESC guidelines for the management of stable coronary artery disease. Eur Heart J. 2013;34:2949\u20133003.","journal-title":"Eur Heart J"},{"key":"6681_CR9","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.cjca.2014.05.013","volume":"30","author":"GBJ Mancini","year":"2014","unstructured":"Mancini GBJ, Gosselin G, Chow B, et al. Canadian cardiovascular society guidelines for the diagnosis and management of stable ischemic heart disease. Can J Cardiol. 2014;30:837\u201349.","journal-title":"Can J Cardiol"},{"key":"6681_CR10","doi-asserted-by":"crossref","unstructured":"Thadani U. The pursuit of optimum outcomes in stable angina. Am J Cardiovasc Drugs 2003; (Suppl 1); pp 11\u201320.","DOI":"10.2165\/00129784-200303001-00002"},{"key":"6681_CR11","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0002-9149(97)00389-5","volume":"80","author":"U Thadani","year":"1997","unstructured":"Thadani U. Management of patients with chronic stable angina at low risk for serious cardiac events. Am J Cardiol. 1997;80:421\u20135.","journal-title":"Am J Cardiol"},{"key":"6681_CR12","unstructured":"Braunwald E, Sobel, B. Coronary blood flow and myocardial ischemia: In Braunwald E, edition, Heart Disease a Textbook of Cardiovascular Medicine, Philadelphia, PA, WB Saunders, 1191, 1998."},{"key":"6681_CR13","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0002-9149(82)90518-5","volume":"49","author":"U Thadani","year":"1982","unstructured":"Thadani U, Fung HL, Darke AC, et al. Oral isosorbide dinitrate in angina pectoris: comparison of duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol. 1982;49:411\u20139.","journal-title":"Am J Cardiol"},{"key":"6681_CR14","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/BF00877415","volume":"8","author":"U Thadani","year":"1994","unstructured":"Thadani U, Lipiky R. Short and long-acting oral nitrates for stable angina. Cardiovasc Drugs Ther. 1994;8:611\u201323.","journal-title":"Cardiovasc Drugs Ther"},{"key":"6681_CR15","doi-asserted-by":"crossref","unstructured":"Thadani U, Lipicky R. Ointments and transdermal nitroglycerin patches for stable angina. Cardiovasc Drugs Ther. 8:625\u201333.","DOI":"10.1007\/BF00877416"},{"key":"6681_CR16","doi-asserted-by":"crossref","unstructured":"Thadani U. Challenges with nitrate therapy and nitrate tolerance: prevalence, prevention, and clinical relevance Am J Cardiovasc Drugs 2014;14 (40):287\u2013301.","DOI":"10.1007\/s40256-014-0072-5"},{"key":"6681_CR17","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1016\/0002-9149(93)90292-K","volume":"72","author":"SG Chrysant","year":"1993","unstructured":"Chrysant SG, Glasser SP, Bittar N, et al. Efficacy and safety of extended-release isosorbide-5-mononitrate in angina pectoris. Am J Cardiol. 1993;72:1249\u201356.","journal-title":"Am J Cardiol"},{"key":"6681_CR18","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1016\/0735-1097(89)90216-7","volume":"13","author":"H DeMots","year":"1989","unstructured":"DeMots H, Glasser SP. On behalf of the Transderm-nitro trial study group. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. JACC. 1989;13:786\u201393.","journal-title":"JACC"},{"key":"6681_CR19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1258\/smj.2011.011274","volume":"57","author":"HL Huang","year":"2012","unstructured":"Huang HL, Fox KA. The impact of beta-blockers on mortality instable angina: a meta-analysis. Scott Med J. 2012;57:69\u201375.","journal-title":"Scott Med J"},{"key":"6681_CR20","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1001\/jama.2012.12559","volume":"308","author":"S Banglore","year":"2012","unstructured":"Banglore S, Steg G, Deedwania P, et al. Beta-blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA. 2012;308:1340\u20139.","journal-title":"JAMA"},{"key":"6681_CR21","doi-asserted-by":"crossref","unstructured":"Heidenreich PA, McDonald KM, Hastie et al. Meta-analysis of trials comparing beta-blockers, calcium antagonists, and nitrates for stable angina. JAMA 1999;281:1927\u20131936","DOI":"10.1001\/jama.281.20.1927"},{"key":"6681_CR22","doi-asserted-by":"crossref","unstructured":"The IONA Study Group. Effect of nicorandil on coronary events in patients with stable angina: the Impact of Nicorandil in angina (IONA) randomized trial. Lancet 2002:359:1269\u20131275.","DOI":"10.1016\/S0140-6736(02)08265-X"},{"key":"6681_CR23","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/0002-9149(90)91129-T","volume":"66","author":"LO Hughes","year":"1990","unstructured":"Hughes LO, El R, Lahiri A, et al. Comparison of nicorandil and atenolol in stable angina pectoris. Am J Cardiol. 1990;66:679\u201382.","journal-title":"Am J Cardiol"},{"key":"6681_CR24","doi-asserted-by":"crossref","unstructured":"Thadani U. Can nicorandil treat angina pectoris effectively \/ Nature Clin Pract Cardio Med 2005 2: 186\u2013187.","DOI":"10.1038\/ncpcardio0159"},{"key":"6681_CR25","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.jacc.2003.11.045","volume":"43","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Skettino S, Parker JO, et al. MARISA investigators. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J Am Coll Cardiol. 2004;43:1375\u201382.","journal-title":"J Am Coll Cardiol"},{"key":"6681_CR26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1001\/jama.291.3.309","volume":"291","author":"BR Chaitman","year":"2004","unstructured":"Chaitman BR, Pepine J, Parker JO, et al. Effects of ranolazine with atenolol,, amlodipine or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina; the CARISA study Group. JAMA. 2004;291:309\u201316.","journal-title":"JAMA"},{"key":"6681_CR27","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/j.jacc.2006.05.044","volume":"48","author":"PH Stone","year":"2006","unstructured":"Stone PH, Gratsiansky NA, Blokhin A, et al. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (efficacy of ranolazine in chronic angina trial. J Am Coll Cardiol. 2006;48:566\u201375.","journal-title":"J Am Coll Cardiol"},{"key":"6681_CR28","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1016\/j.jacc.2013.02.011","volume":"61","author":"M Kosiborod","year":"2013","unstructured":"Kosiborod M, Arnold S, Spertus J, et al. Evaluation of ranolazine in patients with type 2 diabetes and chronic stable angina: results from the TERISSA randomized clinical trial (Type 2 diabetes evaluation in ranolazine subjects with chronic stable angina). J Am Coll Cardiol. 2013;61:2083\u201345.","journal-title":"J Am Coll Cardiol"},{"key":"6681_CR29","doi-asserted-by":"crossref","unstructured":"Weisz G, Genereux P, Lniguez A, Zurakowski A, Schechter M, Alexander KP, Dressler O, Osmukhina A, James S, Magnus O, Ben-Yehuda O, Farzaneh-Far R, Stone GW, for the RIVER-PCI investigators. Ranolazine in patients with incomplete revascularisation after percutaneous coronary intervention (RIVER-PCI): A multicenter, randomized, double-blind, placebo-controlled trial. Lancet 2016;387:136\u2013145","DOI":"10.1016\/S0140-6736(15)00459-6"},{"issue":"17","key":"6681_CR30","doi-asserted-by":"crossref","first-page":"2555","DOI":"10.1517\/14656566.2012.740458","volume":"13","author":"U Thadani","year":"2012","unstructured":"Thadani U. Should ranolazine be used for all patients with ischemic heart disease or only symptomatic patients with stable angina or those with refractory angina pectoris. Expert Opin Pharmacother. 2012;13(17):2555\u201363.","journal-title":"Expert Opin Pharmacother"},{"key":"6681_CR31","first-page":"67","volume":"22","author":"H Szwed","year":"2001","unstructured":"Szwed H, Sadowski Z, Elikowski W, et al. Combination treatment in stable angina using trimetazadine and metoprolol. Eur Heart J. 2001;22:67\u2013274.","journal-title":"Eur Heart J"},{"issue":"5","key":"6681_CR32","first-page":"331","volume":"5","author":"U Thadani","year":"2005","unstructured":"Thadani U. Modified-release formulation of trimetazadine for exceptional control of angina pectoris: fact or fiction. Am J Cardiol. 2005;5(5):331\u20134.","journal-title":"Am J Cardiol"},{"key":"6681_CR33","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1161\/01.CIR.0000048143.25023.87","volume":"107","author":"JS Borer","year":"2003","unstructured":"Borer JS et al. Antianginal and antiischemic effects of ivabradine, an if inhibitor, in stable angina: a randomized, double blind, multicentered, placebo-controlled trial. Circulation. 2003;107:817\u201323.","journal-title":"Circulation"},{"key":"6681_CR34","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1093\/eurheartj\/ehi586","volume":"26","author":"J-C Tardif","year":"2005","unstructured":"Tardif J-C. Ford I, Bourassa M G, et al. efficacy of ivabradine, a new selective if inhibitor, compared with atenolol in patients with chronic stable angina. Eur Heart J. 2005;26:2529\u201336.","journal-title":"Eur Heart J"},{"key":"6681_CR35","doi-asserted-by":"crossref","unstructured":"Tardif J-C, Ponilkowski P, Kahan T, Investigators AS. Efficacy of the if current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4\u00a0month randomized, placebo controlled trial. Eur Heart J. 2009;30:540\u20138.","DOI":"10.1093\/eurheartj\/ehn571"},{"key":"6681_CR36","doi-asserted-by":"crossref","unstructured":"Ruzylow TM, Ford I, Fox KM. Antianginal efficacy and safety of ivabradine compared to amlodipine in patients with stable angina pectoris. A 3\u00a0month randomized, double blind, multicenter, non-inferiority trial. Drugs. 2007;67:393\u2013405.","DOI":"10.2165\/00003495-200767030-00005"},{"key":"6681_CR37","doi-asserted-by":"crossref","unstructured":"Tardif JC, Ponikowiski P, Kahan T. Associate study investigators. Efficacy of the I9f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blockers therapy, a 4\u00a0month, randomized, placebo - controlled trial. Eur Heart J. 2009;30:540\u20138.","DOI":"10.1093\/eurheartj\/ehn571"},{"key":"6681_CR38","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","volume":"372","author":"K Fox","year":"2008","unstructured":"Fox K, Ford I, Steg PG, Tenera M, Ferrari R, BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left ventricular dysfunction (BEAUTIFUL): a randomized, double blind, placebo controlled trial. Lancet. 2008;372:807\u201316.","journal-title":"Lancet"},{"key":"6681_CR39","first-page":"1090","volume":"371","author":"K Fox","year":"2014","unstructured":"Fox K, Ford I, Fleg P, Tardif JC, Tandera M, Ferrari R. Signify investigators. Ivabradine in stable coronary artery disease without clinical heart failure. N Engl J Med. 2014;371:1090\u20139.","journal-title":"N Engl J Med"},{"key":"6681_CR40","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, Boehm M, Borer JS, Ford I, Investigators SHIFT. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomized placebo-controlled study. Lancet. 2010;376:875\u201385.","journal-title":"Lancet"},{"key":"6681_CR41","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1016\/S0140-6736(10)60391-1","volume":"375","author":"A Norman","year":"2010","unstructured":"Norman A, Ang DS, Ogston S, et al. Effect of high dose allopurinol on exercise in patients with chronic stable angina: a randomized, placebo controlled crossover trial. Lancet. 2010;375:2161\u201321167.","journal-title":"Lancet"},{"key":"6681_CR42","doi-asserted-by":"crossref","unstructured":"MERIT-HF Study Group.\u00a0Effect of Metoprolol CR\/XL in Chronic Heart failure: metoprolol CR\/XL randomized Intervention 1996; 335:217-225 Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999:353:2001\u20132007.","DOI":"10.1016\/S0140-6736(99)04440-2"},{"key":"6681_CR43","doi-asserted-by":"crossref","unstructured":"CIBIS-II Investigators and Committees.\u00a0The Cardiac Insufficiency Bisoprolol Stusy II (CIBIS II): a randomized trial. Lancet 1999;353:9\u201313.","DOI":"10.1016\/S0140-6736(98)11181-9"},{"key":"6681_CR44","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1056\/NEJM200105313442201","volume":"344","author":"M Packer","year":"2001","unstructured":"Packer M, Coates AJ, Fowler MD, et al. Carvedilol prospective randomized cummulative survival study group. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med. 2001;344:1651\u20138.","journal-title":"N Engl J Med"},{"key":"6681_CR45","unstructured":"Boden WE, O\u2019Rourke RA, Teo KK, et al. Optimal medical therapy with or without PCI for stable coronary artery disease. N Engl J Med. 2007;356:1503C16."},{"key":"6681_CR46","doi-asserted-by":"crossref","unstructured":"The Bypass Angioplasty Revascularization Investigation (BARI) Investigators.\u00a0Comparison of Coronary Bypass Surgery with Angioplasty in Patients with Multivessel Disease.\u00a0N Eng J Med.\u00a01996;335:217\u201325.","DOI":"10.1056\/NEJM199607253350401"},{"key":"6681_CR47","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1056\/NEJMoa0805796","volume":"360","author":"The BARI","year":"2009","unstructured":"The BARI. 2D study group. A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med. 2009;360:2503\u2013015.","journal-title":"N Engl J Med"},{"key":"6681_CR48","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1161\/CIRCULATIONAHA.110.978247","volume":"123","author":"GR Dagenais","year":"2011","unstructured":"Dagenais GR, Lu J, Faxon DP, et al. BARI 2 study group. Effect of optimal medical treatment with or without coronary revascularization on angina and subsequent revascularization in patents with type 2 diabetes mellitus and stable ischemic heart disease. Circulation. 2011;123:1492\u2013548.","journal-title":"Circulation"},{"key":"6681_CR49","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1001\/jamainternmed.2013.12855","volume":"174","author":"K Stergiopolous","year":"2014","unstructured":"Stergiopolous K, Boden WE, Hartigan P, et al. Percutaneous coronary intervention outcomes in patients with stable obstructive coronary artery disease and myocardial ischemia: a collaborative met-analysis of contemporary randomized clinical trials. JAMA Intern Med. 2014;174:232\u201340.","journal-title":"JAMA Intern Med"},{"key":"6681_CR50","unstructured":"Clinical trials. Gov. International Study of Comparative health effectiveness with Medical and Invasive Approaches (ISCHEMIA). Available at: https:\/\/clinicaltrials.gov\/ct2\/NCT01471522= ."},{"key":"6681_CR51","doi-asserted-by":"crossref","unstructured":"Critchley J., Capewell, S. Smoking cessation for secondary prevention of coronary heart disease Cochrane Database Syst Rev 2004(1):CD003041.","DOI":"10.1002\/14651858.CD003041.pub2"},{"key":"6681_CR52","doi-asserted-by":"crossref","unstructured":"Fillon KB, El Khoury F, Bielinski M, et al. Omega-3fatty acids in high risk cardiovascular patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2010;10:24.","DOI":"10.1186\/1471-2261-10-24"},{"issue":"14","key":"6681_CR53","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJMoa1200303","volume":"368","author":"R Estruch","year":"2013","unstructured":"Estruch R, Ros E, Salas-Salvado J, et al. Primary prevention of cardiovascular disease with a Mediterranean diet. N Engl J Med. 2013;368(14):1279\u201390.","journal-title":"N Engl J Med"},{"key":"6681_CR54","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1136\/heartjnl-2011-301436","volume":"98","author":"RA Henerson","year":"2012","unstructured":"Henerson RA, O\u2019Flynn N. Management of stable angina: summary of NICE guidelines. Heart. 2012;98:500\u20137.","journal-title":"Heart"},{"key":"6681_CR55","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1016\/0140-6736(92)92619-Q","volume":"340","author":"S Juul-Moller","year":"1992","unstructured":"Juul-Moller S, Edvardsson N, Jahnmatz B, et al. Double blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina. The Swedish angina pectoris trial (SAPAT) group. Lancet. 1992;340:1421\u20135.","journal-title":"Lancet"},{"key":"6681_CR56","unstructured":"Scandinavian Simvastatin Survival Study group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4\u00a0s). Lancet. 1994;344:1383\u20139."},{"key":"6681_CR57","doi-asserted-by":"crossref","unstructured":"The SPRINT Research Group.\u00a0A randomized trial of intensive versus standard blood-pressure control.\u00a0N Engl J Med 2015;373:2103\u20132116.","DOI":"10.1056\/NEJMoa1511939"},{"key":"6681_CR58","doi-asserted-by":"crossref","unstructured":"The Accord Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 2010;362:1575\u20131585","DOI":"10.1056\/NEJMoa1001286"},{"key":"6681_CR59","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1056\/NEJMoa1205361","volume":"367","author":"B Bruvne De","year":"2012","unstructured":"De Bruvne B, Piils NHI, Kalesean B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease. N Engl J Med. 2012;367:991\u20131001.","journal-title":"N Engl J Med"}],"container-title":["Cardiovascular Drugs and Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10557-016-6681-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6681-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10557-016-6681-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,13]],"date-time":"2019-09-13T15:47:08Z","timestamp":1568389628000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10557-016-6681-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["6681"],"URL":"https:\/\/doi.org\/10.1007\/s10557-016-6681-2","relation":{},"ISSN":["0920-3206","1573-7241"],"issn-type":[{"value":"0920-3206","type":"print"},{"value":"1573-7241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]}}}